Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

AMRI Burlington Receives DEA Approval to Handle Controlled Substances

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Approval to handle Schedule 2 and 2N controlled substances at this location further supports AMRI SMARTSOURCING™ offering.

AMRI has announced that its Burlington, Mass., site has received approval to expand its current U.S. Drug Enforcement Administration (DEA) registration to handle Schedule 2 and 2N controlled substances.

The license represents the DEA’s acknowledgement of Burlington’s physical security and quality systems, including inventory control and documentation.

With its cGMP aseptic formulation and filling expertise, AMRI Burlington supports pre-clinical through commercial scale production of liquid-filled and lyophilized parenterals.

The addition of Schedule 2 compounds to this registration allows Burlington to perform controlled substance work for its customers, both in the laboratory and on the engineering/production side.

Steven R. Hagen, Ph.D., Senior Vice President of Pharmaceutical Development and Manufacturing at AMRI, said, “As part of its fully integrated global contract services offering, AMRI has the expertise to support cGMP production for a wide spectrum of products across platform technologies, both at the small and large scale. The DEA’s recognition of the security and documentation systems at the Burlington facility is just another example of how AMRI’s formulation and filling capabilities can meet the various needs of the pharmaceutical and biotechnology industries.”

Dr. Hagen continued, “Receiving approval from the DEA to handle controlled substances demonstrates AMRI’s continued ability to offer compliant, quality manufacturing process options to our customers. Our expanded license allows us to continue to build on AMRI SMARTSOURCING™ in the area of manufacturing.”

In DEA terms, Burlington is considered a dosage form manufacturer that can package/label and repackage/relabel. This expanded registration will allow Burlington to offer filling services for Schedule 2, 2N, 3, 3N, 4, and 5 controlled substances, as well as offer these services to complement more of the projects handled by AMRI’s Rensselaer site.

AMRI’s Rensselaer site - which provides contract cGMP manufacturing of bulk active pharmaceuticals and advanced intermediates - holds a DEA controlled substance license permitting the manufacture of Schedule 1 through 5 controlled substances.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AMRI, PerkinElmer to Collaborate on Drug Discovery
Albany Molecular Research (AMRI) and PerkinElmer are collaborating to provide drug discovery infrastructure and services in AMRI's newly launched drug discovery center.
Thursday, June 18, 2015
AMRI to Close Holywell, U.K. API Manufacturing Facility
Company plans to cease operations at the site by the end of 2015.
Thursday, April 09, 2015
AMRI Proposes To Close UK-Based API Manufacturing Facility
The proposed closure would affect approximately 64 positions.
Friday, February 20, 2015
AMRI Announces CFO Transition
Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI.
Thursday, January 15, 2015
AMRI To Acquire Aptuit Drug Product Development Businesses
Significantly expands AMRI's analytical services capabilities and extends drug product development services to include sterile injectable formulation development.
Friday, January 09, 2015
AMRI to Acquire Oso Biopharmaceuticals Manufacturing
Acquisition significantly expands contract manufacturing capabilities to include commercial scale sterile injectables.
Tuesday, June 03, 2014
AMRI to Acquire Cedarburg Pharmaceuticals, Inc.
Broadens contract development and manufacturing capabilities with high value, complex API business.
Friday, March 28, 2014
AMRI Announces Senior Level Leadership Appointment
The appointment of Michael A. Luther, Ph.D. as Senior Vice President of Discovery sees AMRI expanding its biology capabilities.
Thursday, October 17, 2013
AMRI Awarded Contract from the UK Government
Seven-year contract awarded for the development and manufacture of an active ingredient under clinical evaluation.
Thursday, October 03, 2013
FDA Performs Re-inspection of AMRI Burlington MA Facility
Issues Form 483 for three inspectional observations.
Friday, July 26, 2013
AMRI Promotes Susan Collins to Director, Business Development
Ms. Collins is responsible for leading AMRI’s North American Discovery Business Development team.
Tuesday, June 18, 2013
AMRI Announces Appointment of Chairman of the Board of Directors
Company has appointed William S. Marth as Chairman of the Board, effective June 5, 2013.
Friday, June 07, 2013
AMRI and Ono Broaden SMARTSOURCING™ Collaboration
New agreement extends drug discovery and development collaboration between the companies.
Friday, April 26, 2013
AMRI Announces the Promotion of Richard Saffee
Company promotes Mr. Saffee to Vice President and General Manager of large scale manufacturing.
Wednesday, January 09, 2013
AMRI Announces Five-Year Extension of API Supply Agreement with Shire
AMRI enters into a multi-year supply agreement for an undisclosed product.
Tuesday, October 23, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos